995 resultados para 321.7[82]
Resumo:
Os autores apresentam um caso de D. Crohn que inicialmente envolveu localizações comuns, e mais tarde um envolvimento raro - gastro-duodenal. Na altura do diagnóstico definitivo deste último, havia já sinais de obstrução à saída do estômago. A terapêutica com Prednisolona IM e Omeprazole não teve qualquer sucesso, havendo necessidade de recorrer à Cirurgia, como último recurso para resolução da obstrução. Faz-se uma revisão teórica sobre os principais aspectos clínicos, de diagnóstico e terapêutica desta forma rara de envolvimento da D. Crohn.
Resumo:
OBJECTIVE: A familial predisposition to abdominal aortic aneurysms (AAAs) is present in approximately one-fifth of patients. Nevertheless, the clinical implications of a positive family history are not known. We investigated the risk of aneurysm-related complications after endovascular aneurysm repair (EVAR) for patients with and without a positive family history of AAA. METHODS: Patients treated with EVAR for intact AAAs in the Erasmus University Medical Center between 2000 and 2012 were included in the study. Family history was obtained by written questionnaire. Familial AAA (fAAA) was defined as patients having at least one first-degree relative affected with aortic aneurysm. The remaining patients were considered sporadic AAA. Cardiovascular risk factors, aneurysm morphology (aneurysm neck, aneurysm sac, and iliac measurements), and follow-up were obtained prospectively. The primary end point was complications after EVAR, a composite of endoleaks, need for secondary interventions, aneurysm sac growth, acute limb ischemia, and postimplantation rupture. Secondary end points were specific components of the primary end point (presence of endoleak, need for secondary intervention, and aneurysm sac growth), aneurysm neck growth, and overall survival. Kaplan-Meier estimates for the primary end point were calculated and compared using log-rank (Mantel-Cox) test of equality. A Cox-regression model was used to calculate the independent risk of complications associated with fAAA. RESULTS: A total of 255 patients were included in the study (88.6% men; age 72 ± 7 years, median follow-up 3.3 years; interquartile range, 2.2-6.1). A total of 51 patients (20.0%) were classified as fAAA. Patients with fAAA were younger (69 vs 72 years; P = .015) and were less likely to have ever smoked (58.8% vs 73.5%; P = .039). Preoperative aneurysm morphology was similar in both groups. Patients with fAAA had significantly more complications after EVAR (35.3% vs 19.1%; P = .013), with a twofold increased risk (adjusted hazard ratio, 2.1; 95% confidence interval, 1.2-3.7). Secondary interventions (39.2% vs 20.1%; P = .004) and aneurysm sac growth (20.8% vs 9.5%; P = .030) were the most important elements accounting for the difference. Furthermore, a trend toward more type I endoleaks during follow-up was observed (15.6% vs 7.4%; P = .063) and no difference in overall survival. CONCLUSIONS: The current study shows that patients with a familial form of AAA develop more aneurysm-related complications after EVAR, despite similar AAA morphology at baseline. These findings suggest that patients with fAAA form a specific subpopulation and create awareness for a possible increase in the risk of complications after EVAR.
Resumo:
Atualmente verifica-se uma crescente progressão do número de atendimentos de falsas urgências nos serviços de urgência pediátrica. Com o objetivo de identificar fatores psicológicos que possam contribuir para a compreensão da utilização inapropriada destes serviços, foi desenvolvido este estudo descritivo, com abordagem quantitativa. A amostra foi constituída acidentalmentepor 115 díades criança-acompanhante que recorreram inapropriadamente a um serviço de urgência de um hospital pediátrico de Lisboa. Os dados foram recolhidos entre outubro e novembro de 2008 através da consulta da ficha de urgência, da entrevista e de um questionário de crenças e perceções de saúde construído para este estudo. Os resultados revelaram que em 2008 cada criança recorreu em média 5 vezes ao serviço de urgência, e que a recorrência frequente a este serviço está relacionada com as crenças positivas dos acompanhantes, nomeadamente com a confiança e segurança nos cuidados prestados e com a fácil acessibilidade a cuidados e recursos diagnósticos. A perceção da criança como frágil está também associada a uma maior recorrência ao serviço de urgência. Relativamente ao problema de saúde da criança que motivou a procura deste serviço, 52.2% dos acompanhantes consideraram ser grave e 66.1% perceberam-no como urgente. Concluindo, os fatores psicológicos podem contribuir para explicar a utilização inapropriada dos serviços de saúde.
Resumo:
Os autores descrevem, os resultados obtidos em um programa de avaliação sorológica da vacina oral, tipo Sabin, contra a poliomielite, em uma comunidade semi-rural, próxima a cidade do Rio de Janeiro. Em condições controladas 114 crianças, com idades entre 3 meses a 3 anos (Tabela 1) foram vacinadas, com vacinas trivalentes (500.000, 200.000, e 300.000 TCD50 por dose, dos tipos 1, 2 e 3 respectivamente), usando-se três doses, com intervalos de 8 semanas entre as doses. Amostras de sangue foram coletadas por punção venosa ou discos de papel de filtro, juntamente com a 1.ª e a 3.ª dose de vacina e 9 semanas após esta última dose de vacina. As taxas de conversão alcançaram (diluição de sôro 1/8) 82,7%, 98,5% e 75,4% para os tipos 1, 2 e 3 respectivamente, após três doses de vacina (Tabela 2). A distribuição de idade de indivíduos sem anticorpos após a vacinação (Tabela 3) mostra o grupo etário de 1 a 2 anos como o que apresenta a mais baixa taxa de conversão. Os autores acentuam que as condições de vida da população estudada correspondem àquelas de grandes partes da população brasileira, nas áreas rurais do país; e uma avaliação semelhante da vacina em áreas urbanas, seria desejável. Os autores sugerem ainda o aumento da quantidade de vírus do tipo 1 na vacina como medida provàvelmente eficaz na melhora das taxas de conversão em populações como a estudada. Estudos quantitativos sôbre anticorpos para Enterovírus, presentes na população estudada, estão sendo realizados e serão pròximamente apresentados.
Resumo:
Objective: To define the pattern of disease expression and to gain better understanding in patients with juvenile onset systemic lupus erythematosus (SLE) in Portugal. Methods: The features of unselected patients with systemic lupus erythematosus who had disease onset before the age of 18 years were retrospectively analysed in three Portuguese centres with Pediatric Rheumatology Clinic over a 24-year period (1987-2011). Demographic, clinical and laboratory manifestations, therapy and outcome were assessed. Results: A cohort of 56 patients with a mean age at disease onset of 12.6±4.04 years (mean±1SD) (range, 1.0-17.0 years) and a mean period of follow-up of 5.5±5.4 years. Forty six (82.1%) patients were female. The most common disease manifestations were musculoskeletal (87.5%), mucocutaneous (80.3%) and haematological abnormalities (75%). Lupus nephritis was diagnosed in 46.4% of patients and consisted of glomerular ne - phritis in all cases. Neuropsychiatric manifestations occurred in 21.4% but severe central nervous system complications were uncommon, as brain infarcts and organic brain syndrome in 4 (7.1%) patients. Antinuclear antibodies and anti-double stranded DNA were positive in most patients in (98.2% and 71.4% respectively), as well as low C3 and/or C4 were observed frequently (85.7%). Generally, most patients had a good response to therapy as demonstrated by a significant decreasing of SLEDAI score from disease presentation to the last evaluation. The SLEDAI at diagnosis, the maximum SLEDAI and the incidence of complications were significantly higher in patients with neurolupus and/or lupus nephritis. Therapy included oral steroids (87.5%), hydroxychloroquine (85.7%), azathioprine (55.4%), IV cyclophosphamide (28.6%) along with other drugs. Six (10.7%) patients were treated with rituximab. Long-term remission was achieved in 32%, disease was active in 68%, adverse reactions to therapy occurred in 53.6% and complications/severe manifestations in 23.2%. Two patients died, being active disease and severe infection the causes of death. Conclusions: This study suggests that in our patients the clinical and laboratory features observed were similar to juvenile systemic lupus erythematosus patients from other series. Clinical outcome was favourable in the present study. Complications from therapy were frequent. Objective: To define the pattern of disease expression and to gain better understanding in patients with juvenile onset systemic lupus erythematosus (SLE) in Portugal. Methods: The features of unselected patients with systemic lupus erythematosus who had disease onset before the age of 18 years were retrospectively analysed in three Portuguese centres with Pediatric Rheumatology Clinic over a 24-year period (1987-2011). Demographic,clinical and laboratory manifestations, therapy and outcome were assessed. Results: A cohort of 56 patients with a mean age at disease onset of 12.6±4.04 years (mean±1SD) (range, 1.0-17.0 years) and a mean period of follow-up of 5.5±5.4 years. Forty six (82.1%) patients were female. The most common disease manifestations were musculoskeletal (87.5%), mucocutaneous (80.3%) and haematological abnormalities (75%). Lupus nephritis was diagnosed in 46.4% of patients and consisted of glomerular ne - phritis in all cases. Neuropsychiatric manifestations occurred in 21.4% but severe central nervous system complications were uncommon, as brain infarcts and organic brain syndrome in 4 (7.1%) patients. Antinuclear antibodies and anti-double stranded DNA were positive in most patients in (98.2% and 71.4% respectively), as well as low C3 and/or C4 were observed frequently (85.7%). Generally, most patients had a good response to therapy as demonstrated by a significant decreasing of SLEDAI score from disease presentation to the last evaluation. The SLEDAI at diagnosis, the maximum SLEDAI and the incidence of complications were significantly higher in patients with neurolupus and/or lupus nephritis. Therapy included oral steroids (87.5%), hydroxychloroquine (85.7%), azathioprine (55.4%), IV cyclophosphamide (28.6%) along with other drugs. Six (10.7%) patients were treated with rituximab. Long-term remission was achieved in 32%, disease was active in 68%, adverse reactions to therapy occurred in 53.6% and complications/severe manifestations in 23.2%. Two patients died, being active disease and severe infection the causes of death. Conclusions: This study suggests that in our patients the clinical and laboratory features observed were similar to juvenile systemic lupus erythematosus patients from other series. Clinical outcome was favourable in the present study. Complications from therapy were frequent.
Resumo:
O autor apresenta os resultados obtidos na pesquisa de ovos de helmintos, em uma única amostra de fezes coletadas de 1537 escolares, na faixa etária de 7-14 anos, de Escolas Públicas Municipais localizadas em toda a zona urbana de Salvador, utilizando o método de Kato. De um modo geral, os índices encontrados foram bastante elevados, sobretudo em relação ao Trichocephalus trichiurus, alcançando 100% de positivos em deis sub-distritos (Mares e Pilar) e Ascaris lumbricoides, com um percentual máximo de 89,3%. de positivos em São Caetano. Relativamente ao sexo oi percentuais obtidos para Trichocephalus trichiurus, Ascaris lumbricoides e Enterobius vermicularis foram mais altos no sexo feminino, diferindo dos índices de Ancilostomídeos e principalmente, Schistosoma mansoni, os quais foram superiores nos escolares do sexo masculino.
Resumo:
Apresenta-se aqui um estudo retrospectivo de 1340 admissões por intoxicação numa Unidade de Cuidados Intensivos Polivalente durante um período de quatro anos (1986-1989). Em 666 doentes ocorreram 735 intoxicações medicamentosas e em 674 doentes 691 intoxicações não medicamentosas. Nas
intoxicações medicamentosas destacam-se os fármacos com acção principal a nível do sistema nervoso central (82.3%), predominando os insecticidas organofosforados (5 1.2%) nas não medicamentosas. Ao longo dos anos considerados constatou-se uma diminuição absoluta e relativa do número de doentes
intoxicados (480 vs 244, 15.1% vs 9.9%). Dos internados, 698 era do sexo masculino (289 nas intoxicações medicamentosas e 409 nas não medicamentosas) e 642 do sexo feminino (377 nas medicamentosas e 265 nas não medicamentosas), existindo uma diferença estatisticamente muito significativa no tipo
de intoxicação quanto ao sexo (p
Resumo:
Efectuámos angioplastia transiuminal percutânea (ATP) da artéria renal em 59 doentes hipertensos e houve benefício inicial na tensão arterial em 91,5% e tardio em 79,6%. Obtivemos melhores resultados nas lesões unilaterais (81,4%) do que nas bilaterais (72,7%); nas lesões fora do ostium (82,5%) do que nas do ostium (7 1,4%); nas lesões de origem fibromuscular (88,9%) do que nas de origem aterosclerótica(75%); e nos doentes com idade igual ou inferior a 55 anos (84,8%) do que em doentes com idade superior (71,4%). Estas diferenças não foram contudo significativas. Os bons resultados da ATP da artéria renal na hipertensão renovascular levam-nos a considerar esta forma de intervenção como uma alternativa do seu tratamento.
Resumo:
A meningite tuberculosa é uma complicação grave da infecção pelo Mycobacterium tuberculosis. Entre 1 de Janeiro 1989 e 31 de Dezembro de 1995 foram internadas 14 crianças na Unidade de Doenças Infecciosas do Serviço 2 do Hospital D. Estefânia (HDE), por meningite tuberculosa, enquanto nos 6 anos anteriores, tinham sido admitidas 22 crianças, com a mesma patologia. A maioria das crianças tinha idade superior a 5 anos (64%). A fonte de contágio foi identificada em 35,7% dos casos e 79% tinham sido vacinadas com BCG. Em 78,5% foi detectado compromisso neurológico focal. Todas fizeram tratamento com 4 antibacilares. Houve necessidade de intervenção neurocirúrgica em 21% dos doentes. Em 57% dos casos persistiram sequelas neurológicas no final do tratamento. Não se registaram casos de morte.
Resumo:
BACKGROUND: Patient-controlled epidural analgesia with low concentrations of anesthetics is effective in reducing labor pain. The aim of this study was to assess and compare two ultra-low dose regimens of ropivacaine and sufentanil (0.1% ropivacaine plus 0.5 μg.ml-1 sufentanil vs. 0.06% ropivacaine plus 0.5 μg.ml-1 sufentanil) on the intervals between boluses and the duration of labor. MATERIAL AND METHODS: In this non-randomized prospective study, conducted between January and July 2010, two groups of parturients received patient-controlled epidural analgesia: Group I (n = 58; 1 mg.ml-1 ropivacaine + 0.5 μg.ml-1 sufentanil) and Group II (n = 57; 0.6 mg.ml-1 ropivacaine + 0.5 μg.ml-1 sufentanil). Rescue doses of ropivacaine at the concentration of the assigned group without sufentanil were administered as necessary. Pain, local anesthetic requirements, neuraxial blockade characteristics, labor and neonatal outcomes, and maternal satisfaction were recorded. RESULTS: The ropivacaine dose was greater in Group I (9.5 [7.7-12.7] mg.h-1 vs. 6.1 [5.1-9.8 mg.h-1], p < 0.001). A time increase between each bolus was observed in Group I (beta = 32.61 min, 95% CI [25.39; 39.82], p < 0.001), whereas a time decrease was observed in Group II (beta = -1.40 min, 95% CI [-2.44; -0.36], p = 0.009). The duration of the second stage of labor in Group I was significantly longer than that in Group II (78 min vs. 65 min, p < 0.001). CONCLUSIONS: Parturients receiving 0.06% ropivacaine exhibited less evidence of cumulative effects and exhibited faster second stage progression than those who received 0.1% ropivacaine.
Resumo:
Rett syndrome is a neurodevelopmental disorder caused by mutations in the MECP2 gene. We investigated the genetic basis of disease in a female patient with a Rett-like clinical. Karyotype analysis revealed a pericentric inversion in the X chromosome -46,X,inv(X)(p22.1q28), with breakpoints in the cytobands where the MECP2 and CDKL5 genes are located. FISH analysis revealed that the MECP2 gene is not dislocated by the inversion. However, and in spite of a balanced pattern of X inactivation, this patient displayed hypomethylation and an overexpression of the MECP2 gene at the mRNA level in the lymphocytes (mean fold change: 2.55±0.38) in comparison to a group of control individuals; the expression of the CDKL5 gene was similar to that of controls (mean fold change: 0.98±0.10). No gains or losses were detected in the breakpoint regions encompassing known or suspected transcription regulatory elements. We propose that the de-regulation of MECP2 expression in this patient may be due to alterations in long-range genomic interactions caused by the inversion and hypothesize that this type of epigenetic de-regulation of the MECP2 may be present in other RTT-like patients.
Resumo:
Na propedêutica inicial do casal infértil, a realização da Sonossalpingografia (SoSG) contrastada através de dois tipos de ecocontrastes, Echovist® e Levovist®, durante a realização da ultra-sonografia ginecológica convencional pode, em casos seleccionados, substituir como exame de “screening” da permeabilidade tubária a Histerossalpingografia (HSG) e a Laparoscopia com cromotubação (LPC). Objectivos: Comparar os resultados da permeabilidade tubária através da SoSG contrastada com Echovist® ou com Levovist® e a HSG e determinar a sua acuidade em relação a LPC considerada “gold-standard”. Pacientes e métodos: Foram avaliadas prospectivamente 90 pacientes inférteis submetidas a SoSG em que se utilizou o contraste ecogénico Echovist® e 28 pacientes em que se utilizou o eco-realçador Levovist®. Para a HSG utilizou-se, em todas as pacientes, contraste iodado e hidrossolúvel Telebrix®. A observação da permeabilidade tubária teve sua avaliação final e sistemática pela LPC. Resultados: No estudo das trompas pelo Echovist® observamos permeabilidade em 67 pacientes (74,4%) e obstruções bilaterais em 23 das pacientes (25,6%) e pelo Levovist®, respectivamente, 22 (78,6%) e 6 pacientes (21,4%). Na comparação da avaliação da permeabilidade tubária entre a SoSG com Echovist® e LPC encontramos: especificidade € 91,3%, sensibilidade (S) 100%, falsos positivos (FP) 8,7%, falsos negativos (FN) 0%, valor preditivo positivo (VPP) 97,1%, valor preditivo negativo (VPN) 100% e Kappa de 96,5%, e entre a HSG e LPC, neste grupo Echovist® foram: E 100%, S 91,04%, FP 0%, FN 8,96%, VPP 100%, VPN 79,31% e Kappa de 88,6%. Na comparação da avaliação da permeabilidade tubária entre a SoSG com Levovist® e LPC encontramos: E 100%, S 100%, FP 0%, FN 0%, VPP 100%, VPN 100% e Kappa de 100%, e entre a HSG e LPC, no grupo Levovist® foram: E 100%, S 86,36%, FP 0%, FN 13,64%, VPP 100%, VPN 66,67% e Kappa de 82,2%. Conclusões: As Sonossalpingografias (SoSG) contrastadas utilizando-se como eco-realçadores o Echovist® ou o Levovist® podem ser consideradas exames complementares equivalentes na rotina da avaliação inicial do factor tubário por apresentarem, além do mesmo composto químico activo, alta sensibilidade, especificidade e concordância, ambos com acuidade superior à HSG quando comparados com a LPC.
Resumo:
No presente estudo camondongos "Swiss" foram submetidos a tratamento com a droga Ro 7-1051 (N-Benzil-2-Nitro-imidazolacetamida) antes de sua inoculação com a cepa Colombiana do T. cruzi e comparados com animais inocuiados com a mesma cepa e tratados em fase inicial de infecção. Com avaliação feita por parasitemia periférica, xenodiagnõstico, sub-inoculação em camondongos recém-nascidos e exame histopatológico foram obtidos melhores resultados com os animais submetidos a tratamento prévio, tendo-se verificado que 55,5% dos animais permaneceram negativados durante o curso da experiência, enquanto os tratados precocemente tiveram um índice de cura de 28,5%.
Resumo:
Lamivudine has been demonstrated safe and efficacious in the short term in a large cohort of children with chronic hepatitis B (CHB), but optimal duration of treatment has not been elucidated and limited data on the safety of long-term lamivudine administration have been reported. In addition, the durability of favourable therapeutic outcomes after lamivudine therapy in children has not been well characterized. The aim of this study was to examine the safety of lamivudine and the durability of clinical responses in a group of children who received up to 3 years of treatment for CHB. One hundred and fifty-one children from centres in nine countries who had previously received lamivudine in a large prospective trial were enrolled. During the first year, children had been randomized to either lamivudine or placebo treatment. Subsequently, in a separate extension study, those who remained hepatitis B e antigen (HBeAg) positive were given lamivudine for up to 2 years and those who were HBeAg negative were observed for additional 2 years. Results of these studies have been previously reported. In this study, these children were followed for 2 additional years. Data gathered from medical record review included weight, height, signs and symptoms of hepatitis, alanine aminotransferase (ALT) levels, serologic markers, hepatitis B virus (HBV) DNA levels and serious adverse events (SAEs). Other pharmacological treatments for CHB were allowed according to the practices of individual investigators and were documented. Subjects were divided into two groups for analysis, those who had achieved virological response (VR), defined as HBeAg negative and undetectable HBV DNA by the bDNA assay by the end of the extension study at 3 years, and those who had not. In those who had achieved VR by the end of the extension study, long-term durability of HBeAg seroconversion was 82% and >90% in those who had received lamivudine for 52 weeks and at least 2 years respectively. This compares to 75% for those who had achieved seroconversion after placebo. In those who had not achieved VR by the end of the extension study, an additional 11% did so by the end of the study; they had all received lamivudine in the previous trial, and none had received further treatment during the study. Eight children lost hepatitis B surface antigen during the study and all had received lamivudine at some point during the previous trials. Evaluation of safety data revealed no SAEs related to lamivudine. There was no effect of treatment on weight or height z scores. Clinically benign ALT flares (>10 times normal) were seen in 2% of children. Favourable outcomes from lamivudine treatment of CHB in children are maintained for at least several years after completion of treatment. Up to 3 years of lamivudine treatment is safe in children.